PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of clinical oncology

Topics

Chemistry

Biochemistry

Medicine

Cancer Oncology

Pathology

Show all topics

DOI

10.1200/jco.2022.40.6_suppl.011